Valeo Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yondelis (trabectedin) / PharmaMar, J&J
2016-005029-36: Vergleich der Lebensqualität bei Patientinnen mit platinsensitivem wiederkehrenden Eierstock-, Eileiter- und Bachfellkrebs bei der Behandlung mit Trabectedin / PLD oder einer platinbasierten Standardtherapie - eine Kooperation der NOGGO und BNGO

Ongoing
4
206
Europe
Trabectedin, Pegylated liposomal Doxorubicin, Carboplatin, Gemzitabin, Placlitaxel, L01XA02, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, Yondelis 1 mg powder for solution for infusion, Caelyx, Carboplatin, Gemcitabin, Paclitaxel
NOGGO e.V., PharmaMar, S.A.
Ovarian Cancer, cancer of the ovaries, Diseases [C] - Cancer [C04]
 
 
COMPASS, NCT03164980: QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

Terminated
4
89
Europe
Trabectidin (Yondelis)
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar
Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma
08/23
08/23
ACTRN12607000169448: A Phase 3 study comparing the combination of CAELYX and YONDELIS (the study drug) with CAELYX alone in subjects with advanced relapsed ovarian cancer who have previously had platinum based chemotherapy treatment (eg. Carboplatin/Cisplatin)

Recruiting
3
650
 
Johnson & Johnson Pharmaceutical Research & Development, Johnson & Johnson Pharmaceutical Research & Development
Advanced relapsed Ovarian Cancer - to prolong progression free survival
 
 
NCT00707109: Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Recruiting
3
1200
US
trabectedin, Yondelis
University of Medicine and Dentistry New Jersey, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sarcoma
12/09
 
2015-004472-30: overall survival of patients with recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype treated with trabectedin compared to a standard treatment valutare la sopravvivenza globale di pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo con mutazione del BRCA o con fenotipo BRCAness, trattati con trabectedina rispetto ad un trattamento standard

Ongoing
3
244
Europe
Yondelis, ET-743, Powder for solution for injection, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Pharma Mar S.A., Fondazione IRCCS Istituto Nazionale Tumori
recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo che presentino una mutazione del BRCA o il fenotipo BRCAness, patients with recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo che risultano BRCA mutate o hanno il fenotipo BRCAness, Diseases [C] - Cancer [C04]
 
 
2020-005858-21: tTF-NGR Randomized Study - STS tTF-NGR randomisierte Studie - STS

Not yet recruiting
3
126
Europe
tTF-NGR, Yondelis, ET-743, Solution for infusion in pre-filled syringe, Powder for concentrate for solution for infusion, Yondelis
Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel, ANTUREC Pharmaceuticals GmbH
Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)., Patients with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs., Diseases [C] - Cancer [C04]
 
 
MANTRA, NCT04979442 / 2021-001394-23: Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Terminated
3
175
Europe, Canada, US, RoW
RAIN-32, Milademetan, Trabectedin, Yondelis
Rain Oncology Inc, RAIN Therapeutics Inc.
Dedifferentiated Liposarcoma
10/23
10/23
2021-001394-23: Clinical study comparing Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma

Not yet recruiting
3
160
Europe
Milademetan, Trabectedin, DS-3032b, Capsule, Powder for concentrate for solution for infusion
Rain Therapeutics, Inc., Rain Oncology Inc., Rain Therapeuthic Inc, RAIN Therapeutics Inc.
Dedifferentiated liposarcoma, Liposarcoma, Diseases [C] - Cancer [C04]
 
 
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas

Recruiting
3
333
Europe, Canada, US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28
ISG-STS-1001, NCT01710176: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

Active, not recruiting
3
550
Europe
epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3), gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8), trabectedin 1.3 mg/m2, high-dose ifosfamide 14 g/m2, given in in 14 days, etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3), gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
Italian Sarcoma Group, French Sarcoma Group, Grupo Espanol de Investigacion en Sarcomas
Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
06/24
06/24
TRABTRAP, NCT05597917 / 2020-005858-21: tTF-NGR Randomized Study - STS

Recruiting
3
126
Europe
Trabectedin, Yondelis, tTF-NGR
Universität Münster, Anturec Pharmaceuticals GmbH
Soft Tissue Sarcoma
08/26
12/26
A092104, NCT05633381: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Recruiting
2/3
70
US
Olaparib, 763113-22-0, Temozolomide, 85622-93-1, Trabectedin, 114899-77-3, Pazopanib, 444731-52-6, 790713-33-6
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
03/30
03/30
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography Test, TRANSTHORACIC ECHOCARDIOGRAPHY, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
2ND-STEP, jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

Active, not recruiting
2
120
Japan
Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene
Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development
Advanced soft tissue sarcoma
 
 
2006-005009-69: TRABECTEDIN (ET743) IN METASTATIC OR LOCALLY ADVANCED MYXOID/ROUND CELL LIPOSARCOMA PRETREATED WITH CHEMOTHERAPY

Ongoing
2
50
Europe
Trabectedin, ET743, Powder for infusion*
ISTITUTO NAZIONALE PER LA CURA TUMORI
advanced myxoid/round cell liposarcoma pretreated with anthracycline and ifosfamide
 
 
2011-001288-32: Preliminary Study to Evaluate the Safety and Tolerability of the combination ot Trabectidin and Indole-3-Carbinol in advanced breast cancer hormonal receptor positive who failed previous chemioterapy treatment Studio iniziale per valutare la sicurezza e la tollerabilita' della combinazione Trabectidina e Indolo-3-Carbinolo nel tumore della mammella con recettori ormonali positivi in fase avanzata,gia' trattato senza beneficio con terapie precedenti

Ongoing
2
15
Europe
Concentrate for solution for injection, YONDELIS*EV 1FL POLV 1MG
FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE, Pharmamar
Refractory ER-positive metastatic breast cancer Carcinoma mammario metastatico e refrattario ER-positivo, Hormonal receptor positive advanced brast cancer brast cancer who failed previous treatment Tumore mammario con recettori ormonali positivi in fase avanzata che non ha beneficiato di terapie precedenti, Diseases [C] - Cancer [C04]
 
 
2007-006681-15: Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoralbasada en Platino en Pacientes con Cáncer No Microcítico de Pulmón (CNMP)Avanzado con Sobreexpresión de XPG y/o ERCC1, y Subexpresión de BRCA1

Ongoing
2
60
Europe
Yondelis®, ET-743, Yondelis® 0.25 mg and Yondelis® 1 mg, Yondelis® 0.25 mg and Yondelis® 1 mg
Pharma Mar, S.A.
Cáncer no microcítico de pulmón (CNMP) avanzado
 
 
2011-000137-36: USE OF TRABECTEDIN IN PATIENTS WITH RELAPSED/PROGRESSION OF EPITHELIAL CARCINOMA OVARY

Ongoing
2
50
Europe
YONDELIS, CAELYX, YONDELIS, CAELYX
UNIVERSITA, CAMPUS BIOMEDICO
epithelial ovarian carcinoma
 
 
2017-000987-14: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovarian cancer. Studio di fase II:Terapia di mantenimento con Trabectedina dopo terapia di combinazione con Doxorubicina Liposomiale e Trabectedina in pazienti affetti da carcinoma ovarico.

Ongoing
2
130
Europe
Trabectedina, [Trabectedina], Powder for solution for infusion, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
AZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO, Pharma Mar SA
Ovarian cancer Carcinoma ovarico, Ovarian tumour Tumore ovarico, Diseases [C] - Cancer [C04]
 
 
2017-001755-31: Study to Compare a Treatment with Trabectedin and Olaparib to Physician’s Choice in Subjects with Previously Treated Solid Tumors Having a Special lack of Cellular Repair Mechanism Studie zu einer Behandlung mit Trabectedin und Olaparib im Vergleich zu Standardbehandlung nach ärztlichem Ermessen bei Patienten mit soliden Tumoren, die eine gestörte Zellreparatur haben.

Not yet recruiting
2
108
Europe
Trabectedin, Olaparib, ET-743, Powder for concentrate for solution for infusion, Film-coated tablet, Yondelis
Ruprecht-Karls-Universität Heidelberg, Medical Faculty, DKFZ Heidelberg, AstraZeneca GmbH, Pharma Mar S.A.
Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies Patienten mit lokal fortgeschrittenen bzw. metastasierten soliden Organtumoren bei molekulargenetisch nachgewiesenen Störungen im DNA-Reparaturweg, Previously Treated Advanced Tumors Fortgeschrittene Krebserkrankung, die bereits behandelt wurde, Diseases [C] - Cancer [C04]
 
 
2018-000230-35: combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugs studio di trabectedina e olaparib nei tumori dell'ovaio delle tube di falloppio e dei primitivi del peritoneo in stadio avanzato in cui i trattamenti standard a base di platino non hanno più effetto.

Ongoing
2
66
Europe
yondelis, olaparib, [ET-743], [AZD-2281], Powder for solution for injection, Tablet, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS, AstraZeneca
platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum Carcinoma Ovarico, delle tube di Falloppio e dei primitivi del peritoneo platino-resistente, ovarian cancer, fallopian tubes cancer or primary of peritoneum no longer sensitive to standard platinum drugs tumore delle ovaie, delle tube e dei primtivi del peritoneo non più trattabile con i trattamenti standard a base di platino, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
2015-005153-12: Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs) Studio di Fase II con Trabectedina nel trattamento delcarcinosarcoma ovarico o uterino in stadio avanzato

Ongoing
2
43
Europe
YONDELIS, [YONDELIS], Powder for solution for infusion, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Pharma Mar Srl Italy
advanced ovarian and uterine carcinosarcoma carcinosarcoma ovarico o uterino in stadio avanzato, advanced ovarian and uterine carcinosarcoma carcinosarcoma ovarico o uterino in stadio avanzato, Diseases [C] - Cancer [C04]
 
 
2017-004690-14: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36) RECHALLENGE CON DOXORUBICINA LIPOSOMALE PEGILATA IN AGGIUNTA ALLA TRABECTEDINA NELLA RECIDIVA DI TUMORE OVARICO: STUDIO PROSPETTICO MULTICENTRICO (REPRAB study – MITO 36)

Not yet recruiting
2
64
Europe
Trabectedin, Caelyx, [0], Concentrate for solution for injection/infusion, YONDELIS - 025 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO- FLACONCINO (VETRO) 1 FLACONCINO, CAELYX - 2 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO 10 ML USO EV
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Pharma Mar S.A.
Ovarian cancer Carcinoma ovarico, Ovarian cancer Tumore dell'ovaio, Diseases [C] - Cancer [C04]
 
 
2019-003733-41: Study on advanced rearranged Mesenchymal chondrosarcoma Studio per il trattamento dia condrosarcoma mesenchimale (HEY1-NOCOA2 riarrangiato) scheletrico ed extra-scheletrico con malattia avanzata

Not yet recruiting
2
20
Europe
trabectedina, [trabectedina], Powder for infusion, Yondelis
ITALIAN SARCOMA GROUP, Pharma Mar S.A
Patients with advanced, histological and molecularly (presence of the HEY1-NCOA2 fusion) centrally confirmed diagnosis of MCS, with an evidence of RECIST progression within the 6 months prior to starting the study treatment and pre-treated with anthracycline-based chemotherapy Pazienti giovani adulti o adulti affetti da condrosarcoma mesenchimale HEY1-NCOA2 riarrangiato a partenza scheletrica o extra-scheletrica avanzato e in progressione, Advanced Mesenchimal Condrosarcoma Condrosarcoma mesenchimale in fase avanzata, Diseases [C] - Cancer [C04]
 
 
2020-005626-29: A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIOGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE. STUDIO CLINICO DI FASE II, VOLTO A VALUTARE L'ASSOCIAZIONE DEL FARMACO TRABECTEDINA E DEL FARMACO PIOGLITAZONE PPARPg AGONISTA, IN PAZIENTI CON LIPOSARCOMA DI TIPO MIXOIDE/ A CELLULE ROTONDE O LIPOSARCOMA DEDIFFERENZIATO G1 E G2, CON MALATTIA STABILE E IN TRATTAMENTO CON IL FARMACO TRABECTEDINA.

Not yet recruiting
2
10
Europe
Pioglitazone, Trabectedina, [Pioglitazone], [Trabectedina], Tablet, Powder for concentrate for solution for infusion, Pioglitazone, Yondelis
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AIRC (bandi per la ricerca indipendente)
Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluation Pazienti con diagnosi di liposarcoma mixoide/a cellule rotonde trattati per almeno 4 cicli con trabectedina da sola e con malattia stabile in base all’ultima valutazione di malattia., Patients who have been diagnosed with round cell myxoid liposarcoma and who have been treated with only trabectedin and who according to the latest assessment have stable disease. Pazienti con diagnosi di liposarcoma di tipo mixoide/ a cellule rotonde che sono stati trattati negli ultimi 4 cicli con solo il farmaco trabectedina e con malattia stabile all'ultima valutazione., Diseases [C] - Cancer [C04]
 
 
2020-000741-13: Trial assessing the activity of TrabectedIn vs gemCitabine in patients with advanced LEiomyosarcoma Studio sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma avanzato pretrattati c

Not yet recruiting
2
100
Europe
Trabectedina, Gemcitabina, [trabectedina], [Gemcitabina], Powder for infusion, Concentrate for solution for infusion, Yondelis, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2 ML
ITALIAN SARCOMA GROUP, Pharmamar
metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale, advanced Leiomyosarcoma leiomiosarcoma avanzato, Diseases [C] - Cancer [C04]
 
 
2017-001083-38: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas

Not yet recruiting
2
92
Europe
Nivolumab, Trabectedin, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Opdivo®, Yondelis
Universitätsmedizin Greifswald, Bristol-Myers Squibb GmbH und Co. KG, Pharma Mar, S.A.
metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, Diseases [C] - Cancer [C04]
 
 
MITO36, NCT04887961: Reprab Study: PLD + Trabectedin Rechallenge

Recruiting
2
64
Europe
PLD and Trabectedin rechallenge
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Relapsed Ovarian Cancer
04/22
04/22
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Active, not recruiting
2
29
US
Olaparib, Trabectedin
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca
Sarcoma, Sarcoma Metastatic
01/23
01/25
HyperTET, NCT02359474: Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin

Active, not recruiting
2
120
Europe
Trabectedin, Yondelis, DNA double-strand breaks
Ludwig-Maximilians - University of Munich
Sarcoma
08/23
08/23
NCT-PMO-1603, NCT03127215 / 2017-001755-31: Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

Completed
2
102
Europe
Olaparib, Physician's choice, Trabectedin
National Center for Tumor Diseases, Heidelberg, AstraZeneca, PharmaMar, German Cancer Research Center
Cancers With DNA Repair-Deficiency
12/23
12/23
SOC-1882, NCT03886311: Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Recruiting
2
200
US
Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], TVEC, Imlygic, Nivolumab IV Soln 100 MG/10ML, Opdivo, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution, Yondelis
Sarcoma Oncology Research Center, LLC
Sarcoma
12/30
07/31
STRADA, NCT03023124 / 2016-004051-78: Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Completed
2
23
Europe
Trabectedin, Adriamycin, Dacarbazine
Italian Sarcoma Group
Solitary Fibrous Tumors
12/24
12/24
TRABEPIO, NCT04794127: Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.

Recruiting
2
10
Europe
Trabectedin, Trabectedine, Pioglitazone Oral Product, Pioglitazone
Mario Negri Institute for Pharmacological Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Humanitas Hospital, Italy
Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated, Liposarcoma, Round Cell
12/24
02/25
ISG-ARTICLE, NCT04383119 / 2020-000741-13: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting
2
100
Europe
Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort
Italian Sarcoma Group, PharmaMar
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
12/25
12/25
SYNERGIAS, NCT05131386: Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas

Recruiting
2
85
Europe
Trabectedin, Yondelis
Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma, Bone Tumors, Small Round-cell Sarcomas
07/24
07/24
ISG-MCS, NCT04305548 / 2019-003733-41: Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Recruiting
2
16
Europe
Trabectedin
Italian Sarcoma Group, PharmaMar
Mesenchymal Chondrosarcoma
08/25
12/25
TAGGED, NCT04535271: Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

Recruiting
2
80
US
Trabectedin, Gemcitabine, Dacarbazine
Sarcoma Oncology Research Center, LLC
Leiomyosarcoma
09/28
03/29
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting
2
198
Europe
Doxorubicin, Trabectedin, Yondelis
UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole
Leiomyosarcoma Uterus
12/29
12/30
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Completed
2
130
Europe
Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm
Italian Sarcoma Group, PharmaMar, AstraZeneca
Advanced Soft Tissue Sarcoma
11/24
11/24
2014-001549-26: Trial that evaluates the combination treatment of Trabectedin and Radiotherapy in Soft Tissue Sarcoma patients. Ensayo clínico que evalúa la combinación de Trabectedina y Radioterapia para el tratamiento de pacientes con sarcoma de tejidos blandas.

Ongoing
1/2
148
Europe
trabectedina, [trabectedina], Powder for concentrate for solution for infusion, YONDELIS 1 mg powder for concentrate for solution for infusion
GEIS, GRUPO ESPAñOL DE INVESTIGACIóN EN SARCOMAS, PharmaMar, Pharmamar
Soft Tissue Sarcoma Sarcoma de tejidos blandos, Soft Tissue Sarcoma Sarcoma de tejidos blandos, Diseases [C] - Cancer [C04]
 
 
2015-002760-16: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group.

Ongoing
1/2
71
Europe
Coated tablet, Powder for concentrate for solution for infusion, ENDOXAN, YONDELIS
INSTITUT BERGONIE, Pharma Mar S.A., Institut Bergonié
Adult patients with unresectable locally advanced or metastatic soft-tissue sarcoma., Adult patients with unresectable locally advanced or metastatic soft-tissue sarcoma., Diseases [C] - Cancer [C04]
 
 
2009-011041-12: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.

Ongoing
1/2
64
Europe
Yondelis, Oxaliplatin, ET-743, Yondelis 0.25 mg and 1.0 mg, Yondelis 0.25 mg and 1.0 mg
Pharma Mar S.A.
Pretreated Advanced Ovarian Cancer
 
 
TARMIC, NCT02805725: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide

Completed
1/2
50
Europe
Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide, Phase 2: Cyclophosphamide
Institut Bergonié, PharmaMar
Soft-tissue Sarcomas
04/20
12/21
SAINT, NCT03138161: Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Recruiting
1/2
250
US
Trabectedin, Yondelis, Ipilimumab, Yervoy, Nivolumab, Opdivo
Sarcoma Oncology Research Center, LLC, Bristol-Myers Squibb
Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
12/30
07/31
SARC037, NCT04067115: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

Completed
1/2
37
US
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging
Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Ewing Sarcoma
04/25
04/25
TRASTS, NCT02275286: Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Recruiting
1/2
199
Europe
Trabectedin, Yondelis, Radiotherapy
Grupo Espanol de Investigacion en Sarcomas, Centre Leon Berard, Italian Sarcoma Group
Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma, Pleomorphic Liposarcoma
06/28
06/28
TRAMUNE, NCT03085225: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Checkmark From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Sep 2020 - Sep 2020: From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Completed
1
40
Europe
Combination of trabectedin with durvalumab
Institut Bergonié, AstraZeneca, PharmaMar
Ovarian Carcinoma, Soft Tissue Sarcoma
11/20
01/22
OLATRASTS, NCT03985722: Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients

Active, not recruiting
1
28
Europe
Olaratumab and Trabectedin, Lartruvo and Yondelis
Grupo Espanol de Investigacion en Sarcomas
Sarcoma, Soft Tissue
02/21
05/24
NCT01427582: YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

No Longer Available
N/A
US
Trabectedin, YONDELIS
University of Texas Southwestern Medical Center, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Soft Tissue Sarcoma
 
 
NCT00210665: A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

No Longer Available
N/A
US, Canada, RoW
Trabectedin
Janssen Research & Development, LLC
Sarcoma
 
 
GEICO 105-O, NCT05868889: Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD

Completed
N/A
43
Europe
Trabectedin and PLD
Grupo Español de Investigación en Cáncer de Ovario
Ovarian Cancer
06/22
06/22
PIPER, NCT04008238: Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients

Recruiting
N/A
200
Europe
Trabectedin
Institut Bergonié
Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Solitary Fibrous Tumors, Hemangioendothelioma, Desmoplastic Round Cell Tumor, Synovial Sarcoma
01/24
01/25
PROTraSarc, NCT06050434: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients

Completed
N/A
7
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar
Soft Tissue Sarcoma
07/24
07/24
Xadago (safinamide) / Meiji Seika, Zambon, Supernus Pharma
2016-000973-19: Study to verify safety and tolerability of the immediate switch from rasagiline (irreversible MAO-B inhibitor) and safinamide (reversible inhibitor of MAO-B) Studio per verificare la sicurezza e la tollerabilità nel passaggio immediato dal farmaco rasagilina (inibitore MAO-B irreversibile) al farmaco safinamide (inibitore MAO-B reversibile)

Not yet recruiting
4
20
Europe
Xadago, N04BD03, Tablet, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL, IRCCS San Raffaele Pisana
Parkinson's Disease Malattia di Parkinson, Parkinson's Disease Malattia di Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-003254-17: Safety and efficacy of Safinamide (Xadago®) in apathy associated with Parkinson's disease Seguridad y eficacia de la Safinamida (Xadago®) en la apatía asociada a la enfermedad de Parkinson

Ongoing
4
36
Europe
Film-coated tablet, Xadago
Institut de Recerca Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital de la Santa Creu i Sant Pau
Parkinson's disease Enfermedad de Parkinson, Parkinson's disease Enfermedad de Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002239-41: Effects of Safinamide therapy on reuroplasticity in patients with Parkinson's disease Effetti della safinamide in pazienti con malattia di Parkinson

Not yet recruiting
4
40
Europe
Xadago 50mg, NO4BD03, Film-coated tablet, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
I.R.C.C.S. FONDAZIONE S.LUCIA, Fondazione Santa Lucia
Parkinson's disease Malattia di Parkinson, Parkinson's disease Malattia di Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05312632: A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Completed
4
201
RoW
Safinamide Mesilate, Equfina, ME2125
Eisai Korea Inc.
Parkinson Disease
05/23
05/23
NCT03968744: Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Recruiting
4
23
Europe
Safinamide, Xadago
Alain Kaelin, Clinical Trial Unit Ente Ospedaliero Cantonale
Idiopathic Parkinson's Disease (at Later Stage)
04/25
04/25
2018-004892-11: A randomized, double-blind, placebo controlled, multicentre study to evaluate the effect of safinamide on freezing of gait (FOG) in mid- to late-stage fluctuating PD patients Studio multicentrico randomizzato, in doppio cieco, controllato con placebo di valutazione dell’effetto della safinamide sul freezing della marcia nei pazienti con malattia di parkinson in fase medio-avanzata

Not yet recruiting
3
128
Europe
Xadago, [043906039], Tablet, XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
OSPEDALE SANTA MARIA DELLA MISERICORDIA, Zambon s.p.a.
• Subjects of both genders over 18 years of age, with a clinical diagnosis of idiopathic PD• A Modified Hoehn and Yahr stage of = 4 in the “off” state;• A stable (4 weeks since last modification) anti-parkinsonian therapy; • The presence of FOG (defined as the persistence of gait hesitation and failure in starting the gait or the reported sensation of having the legs “frozen” or “glued to the ground”) even on an optimized dopaminergic treatment (patients with FOG item 3 score >0) • Soggetti maggiorenni con Malattia di Parkinson idiopatica;• Stadio Hoehn e Yahr di = 4 nello stato "off";• Una terapia antiparkinsoniana stabile (4 settimane dopo l'ultima modifica)• La presenza di FOG (definita come la persistenza di esitazione dell'andatura e fallimento nell'avvio dell'andatura o la sensazione riportata di avere le gambe "congelate" o "incollate a terra") anche su un trattamento dopaminergico ottimizzato (pazienti con punteggio all’item 3 del FOG-Q > 0), idiopathic Parkinson's disease (H & Y: = 4 in "off"); in stable therapy with hesitation of gait and failure to start gait or the feeling of having legs "glue to the ground" M. di Parkinson idiopatica (H&Y: = 4 in "off"); in terapia stabile con esitazione dell'andatura e fallimento nell'avvio dell'andatura o la sensazione riportata di avere le gambe "incollate a terra", Diseases [C] - Nervous System Diseases [C10]
 
 
SUCCESS, NCT03994328: An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD

Completed
N/A
1235
Europe
Zambon SpA, Iqvia Pty Ltd
Parkinson's Disease
12/23
12/23
NCT05225324: A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

Completed
N/A
702
RoW
Equfina 50 mg
Eisai Korea Inc.
Parkinson Disease
03/25
03/25
Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium

Not yet recruiting
3
28
Europe
QMF149, QVM149, Inhalation powder
University Medical Center Groningen, Novartis Pharma AG
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05562466: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Recruiting
3
200
Europe, RoW
QMF149, Budesonide
Novartis Pharmaceuticals
Asthma
02/28
05/28
NCT06077019: Role of Lung Function for Exercise Capacity in Well-trained Individuals

Recruiting
N/A
60
Europe
Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo
Morten Hostrup, PhD
Exercise Performance
07/26
12/26
NCT06067100: U-LABA/ICS Effects on Exercise Performance, Indacaterol

Recruiting
N/A
30
Europe
Indacaterol and Mometasonefluroate (low dose), Placebo, Indacaterol and Mometasonefluroate (high dose)
Morten Hostrup, PhD
Exercise Performance
07/26
12/26
NCT05217810: A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

Recruiting
N/A
600
RoW
Atectura inhalation capsule (150/80ug), Atectura inhalation capsule (150/160ug), Atectura inhalation capsule (150/320ug)
Novartis Pharmaceuticals
Asthma
12/26
12/26
Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
NCT05776927: A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Not yet recruiting
3
304
NA
QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149, Placebo to Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication, Rescue Medication, Concept 1 Device, Girohaler
Novartis Pharmaceuticals
Asthma
03/26
02/29
ADITION, NCT04656223: Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions

Completed
N/A
434
Europe
MF/IND/GLY plus sensor system, FDC therapy
Novartis Pharmaceuticals
Asthma
01/23
01/23
ChiCTR2300079273: Effect of Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose triple formulation on pulmonary function, symptoms and inflammation control in patients with asthma complicated with COPD

Not yet recruiting
N/A
96
 
Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose (160/150/50μg,qd); Budesonide formoterol inhalation powder aerosol (160/4.5 micrograms, 2 inhalations per bid) plus tiotropium bromide inhaler (2.5 micrograms, once a day, 2 inhalations per inhalation); Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol (160/4.8/7.2μg,bid,2 inhalations per inhalation)
Lishui People's Hospital; LiShui people's hospital, China Medical Foundation
asthma-COPD overlap
 
 
NCT05274425: A 24-week rPMS Study in Real-world Setting for Enerzair

Recruiting
N/A
600
RoW
Enerzair 150/50/80 μg, Enerzair 150/50/160 μg
Novartis Pharmaceuticals
Asthma
03/27
03/27
sabizabulin (VERU-111) / Veru Inc, Valeo Pharma
2021-001194-24: Clinical trial to Assess the Efficacy and Safety of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

Not yet recruiting
3
210
Europe
VERU-111, Capsule
Veru Inc., Veru Inc.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS), Coronavirus disease 2019 (COVID-19) in Patients at High Risk for Acute Respiratory Distress Syndrome, Diseases [C] - Virus Diseases [C02]
 
 
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
NCT03752099: To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Terminated
1b/2
80
US
VERU-111, Bisindole
Veru Inc.
Metastatic Castration Resistant Prostate Cancer
03/23
03/23
Redesca (low molecular weight heparin biosimilar) / Valeo Pharma
PRIORITY, NCT06153394: Prolonged Hypercoagulability Following Major Liver Resection for Malignancy

Not yet recruiting
3
50
Canada
Redesca (enoxaparin sodium for injection), Fragmin (dalteparin)
Western University, Canada, Valeo Pharma Inc
Hepatic Disease, Surgery-Complications, Hypercoagulability, Thrombosis
02/25
02/28
Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
2013-000581-10: Examining the effects of eye drops on changes in inflammation on the surface of the eye

Ongoing
4
100
Europe
latanoprost, travaprost, bimatoprost, tafluprost, Timolol maleate, Brimonidine tartrate, Brinzolamide, Dorzolamide hydrochloride, pilocarpine hydrochloride, Pilocarpine nitrate, N/A, Eye drops, solution, Eye drops, , Xalatan, Travatan, Lumigan, Saflutan, Timptol, Trusopt, Pilocarpine hydrochloride, N/A
Nottingham University NHS Trust
Glaucoma is the condition that is being treated by these eye drops - however the study is aimed at measuring the amount of inflammation that develops on the surface of the eye when these drops are used, Diseases [C] - Eye Diseases [C11]
 
 
NCT06883123: Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Recruiting
4
70
US
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Prairie Eye Center, Sengi
Open Angle Glaucoma
04/26
04/26
2020-000079-18: A phase III, multicentre, prospective, randomized, assessor-blinded, two-arm, parallel group, therapeutic non-inferiority 3-month clinical trial to compare the efficacy and safety of a generic fixed combination of brinzolamide 10 mg/mL + brimonidine tartrate 2 mg/mL eye drops suspension (Pharmathen) versus SIMBRINZA®/Alcon 10 mg/mL + 2 mg/mL eye drops suspension in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension

Ongoing
3
200
Europe
brinzolamide 10 mg/mL + brimonidine tartrate 2 mg/mL, SIMBRINZA, Eye drops, suspension, SIMBRINZA
Pharmathen S.A., Pharmathen S.A.
Open-angle glaucoma (OAG) or ocular hypertension (OHT) Γλαύκωμα ανοιχτής γωνίας ή ενδοφθάλμια υπερτονία, Glaucoma is a progressive multifactorial complex chronic optic neuropathy that constitutes a leading cause of irreversible blindness worldwide, with OAG being the most common form of the disease, Diseases [C] - Eye Diseases [C11]
 
 
ChiCTR1800015147: Measurement of the Rates of Retinal Nerve Fiber Layer Thinning to Guide Management of Myopic Glaucoma Patients

Suspended
N/A
203
 
Phase I: latanoprost 0.005% vs brinzolamide1%/brimonidine 0.2%. Phase II: Additional IOP lowering by 20% vs. continued treatment.
The Chinese University of Hong Kong; Level of the institution：, General Research Fund
Myopic Glaucoma
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yondelis (trabectedin) / PharmaMar, J&J
2016-005029-36: Vergleich der Lebensqualität bei Patientinnen mit platinsensitivem wiederkehrenden Eierstock-, Eileiter- und Bachfellkrebs bei der Behandlung mit Trabectedin / PLD oder einer platinbasierten Standardtherapie - eine Kooperation der NOGGO und BNGO

Ongoing
4
206
Europe
Trabectedin, Pegylated liposomal Doxorubicin, Carboplatin, Gemzitabin, Placlitaxel, L01XA02, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, Yondelis 1 mg powder for solution for infusion, Caelyx, Carboplatin, Gemcitabin, Paclitaxel
NOGGO e.V., PharmaMar, S.A.
Ovarian Cancer, cancer of the ovaries, Diseases [C] - Cancer [C04]
 
 
COMPASS, NCT03164980: QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

Terminated
4
89
Europe
Trabectidin (Yondelis)
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar
Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma
08/23
08/23
ACTRN12607000169448: A Phase 3 study comparing the combination of CAELYX and YONDELIS (the study drug) with CAELYX alone in subjects with advanced relapsed ovarian cancer who have previously had platinum based chemotherapy treatment (eg. Carboplatin/Cisplatin)

Recruiting
3
650
 
Johnson & Johnson Pharmaceutical Research & Development, Johnson & Johnson Pharmaceutical Research & Development
Advanced relapsed Ovarian Cancer - to prolong progression free survival
 
 
NCT00707109: Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Recruiting
3
1200
US
trabectedin, Yondelis
University of Medicine and Dentistry New Jersey, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sarcoma
12/09
 
2015-004472-30: overall survival of patients with recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype treated with trabectedin compared to a standard treatment valutare la sopravvivenza globale di pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo con mutazione del BRCA o con fenotipo BRCAness, trattati con trabectedina rispetto ad un trattamento standard

Ongoing
3
244
Europe
Yondelis, ET-743, Powder for solution for injection, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Pharma Mar S.A., Fondazione IRCCS Istituto Nazionale Tumori
recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo che presentino una mutazione del BRCA o il fenotipo BRCAness, patients with recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype pazienti con recidiva di tumore ovarico, delle tube di Falloppio o primitivo del peritoneo che risultano BRCA mutate o hanno il fenotipo BRCAness, Diseases [C] - Cancer [C04]
 
 
2020-005858-21: tTF-NGR Randomized Study - STS tTF-NGR randomisierte Studie - STS

Not yet recruiting
3
126
Europe
tTF-NGR, Yondelis, ET-743, Solution for infusion in pre-filled syringe, Powder for concentrate for solution for infusion, Yondelis
Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel, ANTUREC Pharmaceuticals GmbH
Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)., Patients with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs., Diseases [C] - Cancer [C04]
 
 
MANTRA, NCT04979442 / 2021-001394-23: Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Terminated
3
175
Europe, Canada, US, RoW
RAIN-32, Milademetan, Trabectedin, Yondelis
Rain Oncology Inc, RAIN Therapeutics Inc.
Dedifferentiated Liposarcoma
10/23
10/23
2021-001394-23: Clinical study comparing Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma

Not yet recruiting
3
160
Europe
Milademetan, Trabectedin, DS-3032b, Capsule, Powder for concentrate for solution for infusion
Rain Therapeutics, Inc., Rain Oncology Inc., Rain Therapeuthic Inc, RAIN Therapeutics Inc.
Dedifferentiated liposarcoma, Liposarcoma, Diseases [C] - Cancer [C04]
 
 
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas

Recruiting
3
333
Europe, Canada, US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28
ISG-STS-1001, NCT01710176: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

Active, not recruiting
3
550
Europe
epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3), gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8), trabectedin 1.3 mg/m2, high-dose ifosfamide 14 g/m2, given in in 14 days, etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3), gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
Italian Sarcoma Group, French Sarcoma Group, Grupo Espanol de Investigacion en Sarcomas
Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
06/24
06/24
TRABTRAP, NCT05597917 / 2020-005858-21: tTF-NGR Randomized Study - STS

Recruiting
3
126
Europe
Trabectedin, Yondelis, tTF-NGR
Universität Münster, Anturec Pharmaceuticals GmbH
Soft Tissue Sarcoma
08/26
12/26
A092104, NCT05633381: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Recruiting
2/3
70
US
Olaparib, 763113-22-0, Temozolomide, 85622-93-1, Trabectedin, 114899-77-3, Pazopanib, 444731-52-6, 790713-33-6
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
03/30
03/30
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography Test, TRANSTHORACIC ECHOCARDIOGRAPHY, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
2ND-STEP, jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

Active, not recruiting
2
120
Japan
Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene
Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development
Advanced soft tissue sarcoma
 
 
2006-005009-69: TRABECTEDIN (ET743) IN METASTATIC OR LOCALLY ADVANCED MYXOID/ROUND CELL LIPOSARCOMA PRETREATED WITH CHEMOTHERAPY

Ongoing
2
50
Europe
Trabectedin, ET743, Powder for infusion*
ISTITUTO NAZIONALE PER LA CURA TUMORI
advanced myxoid/round cell liposarcoma pretreated with anthracycline and ifosfamide
 
 
2011-001288-32: Preliminary Study to Evaluate the Safety and Tolerability of the combination ot Trabectidin and Indole-3-Carbinol in advanced breast cancer hormonal receptor positive who failed previous chemioterapy treatment Studio iniziale per valutare la sicurezza e la tollerabilita' della combinazione Trabectidina e Indolo-3-Carbinolo nel tumore della mammella con recettori ormonali positivi in fase avanzata,gia' trattato senza beneficio con terapie precedenti

Ongoing
2
15
Europe
Concentrate for solution for injection, YONDELIS*EV 1FL POLV 1MG
FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE, Pharmamar
Refractory ER-positive metastatic breast cancer Carcinoma mammario metastatico e refrattario ER-positivo, Hormonal receptor positive advanced brast cancer brast cancer who failed previous treatment Tumore mammario con recettori ormonali positivi in fase avanzata che non ha beneficiato di terapie precedenti, Diseases [C] - Cancer [C04]
 
 
2007-006681-15: Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoralbasada en Platino en Pacientes con Cáncer No Microcítico de Pulmón (CNMP)Avanzado con Sobreexpresión de XPG y/o ERCC1, y Subexpresión de BRCA1

Ongoing
2
60
Europe
Yondelis®, ET-743, Yondelis® 0.25 mg and Yondelis® 1 mg, Yondelis® 0.25 mg and Yondelis® 1 mg
Pharma Mar, S.A.
Cáncer no microcítico de pulmón (CNMP) avanzado
 
 
2011-000137-36: USE OF TRABECTEDIN IN PATIENTS WITH RELAPSED/PROGRESSION OF EPITHELIAL CARCINOMA OVARY

Ongoing
2
50
Europe
YONDELIS, CAELYX, YONDELIS, CAELYX
UNIVERSITA, CAMPUS BIOMEDICO
epithelial ovarian carcinoma
 
 
2017-000987-14: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovarian cancer. Studio di fase II:Terapia di mantenimento con Trabectedina dopo terapia di combinazione con Doxorubicina Liposomiale e Trabectedina in pazienti affetti da carcinoma ovarico.

Ongoing
2
130
Europe
Trabectedina, [Trabectedina], Powder for solution for infusion, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
AZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO, Pharma Mar SA
Ovarian cancer Carcinoma ovarico, Ovarian tumour Tumore ovarico, Diseases [C] - Cancer [C04]
 
 
2017-001755-31: Study to Compare a Treatment with Trabectedin and Olaparib to Physician’s Choice in Subjects with Previously Treated Solid Tumors Having a Special lack of Cellular Repair Mechanism Studie zu einer Behandlung mit Trabectedin und Olaparib im Vergleich zu Standardbehandlung nach ärztlichem Ermessen bei Patienten mit soliden Tumoren, die eine gestörte Zellreparatur haben.

Not yet recruiting
2
108
Europe
Trabectedin, Olaparib, ET-743, Powder for concentrate for solution for infusion, Film-coated tablet, Yondelis
Ruprecht-Karls-Universität Heidelberg, Medical Faculty, DKFZ Heidelberg, AstraZeneca GmbH, Pharma Mar S.A.
Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies Patienten mit lokal fortgeschrittenen bzw. metastasierten soliden Organtumoren bei molekulargenetisch nachgewiesenen Störungen im DNA-Reparaturweg, Previously Treated Advanced Tumors Fortgeschrittene Krebserkrankung, die bereits behandelt wurde, Diseases [C] - Cancer [C04]
 
 
2018-000230-35: combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugs studio di trabectedina e olaparib nei tumori dell'ovaio delle tube di falloppio e dei primitivi del peritoneo in stadio avanzato in cui i trattamenti standard a base di platino non hanno più effetto.

Ongoing
2
66
Europe
yondelis, olaparib, [ET-743], [AZD-2281], Powder for solution for injection, Tablet, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS, AstraZeneca
platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum Carcinoma Ovarico, delle tube di Falloppio e dei primitivi del peritoneo platino-resistente, ovarian cancer, fallopian tubes cancer or primary of peritoneum no longer sensitive to standard platinum drugs tumore delle ovaie, delle tube e dei primtivi del peritoneo non più trattabile con i trattamenti standard a base di platino, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
2015-005153-12: Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs) Studio di Fase II con Trabectedina nel trattamento delcarcinosarcoma ovarico o uterino in stadio avanzato

Ongoing
2
43
Europe
YONDELIS, [YONDELIS], Powder for solution for infusion, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Pharma Mar Srl Italy
advanced ovarian and uterine carcinosarcoma carcinosarcoma ovarico o uterino in stadio avanzato, advanced ovarian and uterine carcinosarcoma carcinosarcoma ovarico o uterino in stadio avanzato, Diseases [C] - Cancer [C04]
 
 
2017-004690-14: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36) RECHALLENGE CON DOXORUBICINA LIPOSOMALE PEGILATA IN AGGIUNTA ALLA TRABECTEDINA NELLA RECIDIVA DI TUMORE OVARICO: STUDIO PROSPETTICO MULTICENTRICO (REPRAB study – MITO 36)

Not yet recruiting
2
64
Europe
Trabectedin, Caelyx, [0], Concentrate for solution for injection/infusion, YONDELIS - 025 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO- FLACONCINO (VETRO) 1 FLACONCINO, CAELYX - 2 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO 10 ML USO EV
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Pharma Mar S.A.
Ovarian cancer Carcinoma ovarico, Ovarian cancer Tumore dell'ovaio, Diseases [C] - Cancer [C04]
 
 
2019-003733-41: Study on advanced rearranged Mesenchymal chondrosarcoma Studio per il trattamento dia condrosarcoma mesenchimale (HEY1-NOCOA2 riarrangiato) scheletrico ed extra-scheletrico con malattia avanzata

Not yet recruiting
2
20
Europe
trabectedina, [trabectedina], Powder for infusion, Yondelis
ITALIAN SARCOMA GROUP, Pharma Mar S.A
Patients with advanced, histological and molecularly (presence of the HEY1-NCOA2 fusion) centrally confirmed diagnosis of MCS, with an evidence of RECIST progression within the 6 months prior to starting the study treatment and pre-treated with anthracycline-based chemotherapy Pazienti giovani adulti o adulti affetti da condrosarcoma mesenchimale HEY1-NCOA2 riarrangiato a partenza scheletrica o extra-scheletrica avanzato e in progressione, Advanced Mesenchimal Condrosarcoma Condrosarcoma mesenchimale in fase avanzata, Diseases [C] - Cancer [C04]
 
 
2020-005626-29: A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIOGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE. STUDIO CLINICO DI FASE II, VOLTO A VALUTARE L'ASSOCIAZIONE DEL FARMACO TRABECTEDINA E DEL FARMACO PIOGLITAZONE PPARPg AGONISTA, IN PAZIENTI CON LIPOSARCOMA DI TIPO MIXOIDE/ A CELLULE ROTONDE O LIPOSARCOMA DEDIFFERENZIATO G1 E G2, CON MALATTIA STABILE E IN TRATTAMENTO CON IL FARMACO TRABECTEDINA.

Not yet recruiting
2
10
Europe
Pioglitazone, Trabectedina, [Pioglitazone], [Trabectedina], Tablet, Powder for concentrate for solution for infusion, Pioglitazone, Yondelis
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AIRC (bandi per la ricerca indipendente)
Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluation Pazienti con diagnosi di liposarcoma mixoide/a cellule rotonde trattati per almeno 4 cicli con trabectedina da sola e con malattia stabile in base all’ultima valutazione di malattia., Patients who have been diagnosed with round cell myxoid liposarcoma and who have been treated with only trabectedin and who according to the latest assessment have stable disease. Pazienti con diagnosi di liposarcoma di tipo mixoide/ a cellule rotonde che sono stati trattati negli ultimi 4 cicli con solo il farmaco trabectedina e con malattia stabile all'ultima valutazione., Diseases [C] - Cancer [C04]
 
 
2020-000741-13: Trial assessing the activity of TrabectedIn vs gemCitabine in patients with advanced LEiomyosarcoma Studio sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma avanzato pretrattati c

Not yet recruiting
2
100
Europe
Trabectedina, Gemcitabina, [trabectedina], [Gemcitabina], Powder for infusion, Concentrate for solution for infusion, Yondelis, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2 ML
ITALIAN SARCOMA GROUP, Pharmamar
metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale, advanced Leiomyosarcoma leiomiosarcoma avanzato, Diseases [C] - Cancer [C04]
 
 
2017-001083-38: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas

Not yet recruiting
2
92
Europe
Nivolumab, Trabectedin, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Opdivo®, Yondelis
Universitätsmedizin Greifswald, Bristol-Myers Squibb GmbH und Co. KG, Pharma Mar, S.A.
metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, Diseases [C] - Cancer [C04]
 
 
MITO36, NCT04887961: Reprab Study: PLD + Trabectedin Rechallenge

Recruiting
2
64
Europe
PLD and Trabectedin rechallenge
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Relapsed Ovarian Cancer
04/22
04/22
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Active, not recruiting
2
29
US
Olaparib, Trabectedin
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca
Sarcoma, Sarcoma Metastatic
01/23
01/25
HyperTET, NCT02359474: Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin

Active, not recruiting
2
120
Europe
Trabectedin, Yondelis, DNA double-strand breaks
Ludwig-Maximilians - University of Munich
Sarcoma
08/23
08/23
NCT-PMO-1603, NCT03127215 / 2017-001755-31: Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

Completed
2
102
Europe
Olaparib, Physician's choice, Trabectedin
National Center for Tumor Diseases, Heidelberg, AstraZeneca, PharmaMar, German Cancer Research Center
Cancers With DNA Repair-Deficiency
12/23
12/23
SOC-1882, NCT03886311: Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Recruiting
2
200
US
Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], TVEC, Imlygic, Nivolumab IV Soln 100 MG/10ML, Opdivo, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution, Yondelis
Sarcoma Oncology Research Center, LLC
Sarcoma
12/30
07/31
STRADA, NCT03023124 / 2016-004051-78: Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Completed
2
23
Europe
Trabectedin, Adriamycin, Dacarbazine
Italian Sarcoma Group
Solitary Fibrous Tumors
12/24
12/24
TRABEPIO, NCT04794127: Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.

Recruiting
2
10
Europe
Trabectedin, Trabectedine, Pioglitazone Oral Product, Pioglitazone
Mario Negri Institute for Pharmacological Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Humanitas Hospital, Italy
Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated, Liposarcoma, Round Cell
12/24
02/25
ISG-ARTICLE, NCT04383119 / 2020-000741-13: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting
2
100
Europe
Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort
Italian Sarcoma Group, PharmaMar
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
12/25
12/25
SYNERGIAS, NCT05131386: Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas

Recruiting
2
85
Europe
Trabectedin, Yondelis
Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma, Bone Tumors, Small Round-cell Sarcomas
07/24
07/24
ISG-MCS, NCT04305548 / 2019-003733-41: Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Recruiting
2
16
Europe
Trabectedin
Italian Sarcoma Group, PharmaMar
Mesenchymal Chondrosarcoma
08/25
12/25
TAGGED, NCT04535271: Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

Recruiting
2
80
US
Trabectedin, Gemcitabine, Dacarbazine
Sarcoma Oncology Research Center, LLC
Leiomyosarcoma
09/28
03/29
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting
2
198
Europe
Doxorubicin, Trabectedin, Yondelis
UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole
Leiomyosarcoma Uterus
12/29
12/30
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Completed
2
130
Europe
Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm
Italian Sarcoma Group, PharmaMar, AstraZeneca
Advanced Soft Tissue Sarcoma
11/24
11/24
2014-001549-26: Trial that evaluates the combination treatment of Trabectedin and Radiotherapy in Soft Tissue Sarcoma patients. Ensayo clínico que evalúa la combinación de Trabectedina y Radioterapia para el tratamiento de pacientes con sarcoma de tejidos blandas.

Ongoing
1/2
148
Europe
trabectedina, [trabectedina], Powder for concentrate for solution for infusion, YONDELIS 1 mg powder for concentrate for solution for infusion
GEIS, GRUPO ESPAñOL DE INVESTIGACIóN EN SARCOMAS, PharmaMar, Pharmamar
Soft Tissue Sarcoma Sarcoma de tejidos blandos, Soft Tissue Sarcoma Sarcoma de tejidos blandos, Diseases [C] - Cancer [C04]
 
 
2015-002760-16: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group.

Ongoing
1/2
71
Europe
Coated tablet, Powder for concentrate for solution for infusion, ENDOXAN, YONDELIS
INSTITUT BERGONIE, Pharma Mar S.A., Institut Bergonié
Adult patients with unresectable locally advanced or metastatic soft-tissue sarcoma., Adult patients with unresectable locally advanced or metastatic soft-tissue sarcoma., Diseases [C] - Cancer [C04]
 
 
2009-011041-12: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.

Ongoing
1/2
64
Europe
Yondelis, Oxaliplatin, ET-743, Yondelis 0.25 mg and 1.0 mg, Yondelis 0.25 mg and 1.0 mg
Pharma Mar S.A.
Pretreated Advanced Ovarian Cancer
 
 
TARMIC, NCT02805725: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide

Completed
1/2
50
Europe
Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide, Phase 2: Cyclophosphamide
Institut Bergonié, PharmaMar
Soft-tissue Sarcomas
04/20
12/21
SAINT, NCT03138161: Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Recruiting
1/2
250
US
Trabectedin, Yondelis, Ipilimumab, Yervoy, Nivolumab, Opdivo
Sarcoma Oncology Research Center, LLC, Bristol-Myers Squibb
Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
12/30
07/31
SARC037, NCT04067115: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

Completed
1/2
37
US
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging
Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Ewing Sarcoma
04/25
04/25
TRASTS, NCT02275286: Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Recruiting
1/2
199
Europe
Trabectedin, Yondelis, Radiotherapy
Grupo Espanol de Investigacion en Sarcomas, Centre Leon Berard, Italian Sarcoma Group
Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma, Pleomorphic Liposarcoma
06/28
06/28
TRAMUNE, NCT03085225: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Checkmark From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Sep 2020 - Sep 2020: From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Completed
1
40
Europe
Combination of trabectedin with durvalumab
Institut Bergonié, AstraZeneca, PharmaMar
Ovarian Carcinoma, Soft Tissue Sarcoma
11/20
01/22
OLATRASTS, NCT03985722: Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients

Active, not recruiting
1
28
Europe
Olaratumab and Trabectedin, Lartruvo and Yondelis
Grupo Espanol de Investigacion en Sarcomas
Sarcoma, Soft Tissue
02/21
05/24
NCT01427582: YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

No Longer Available
N/A
US
Trabectedin, YONDELIS
University of Texas Southwestern Medical Center, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Soft Tissue Sarcoma
 
 
NCT00210665: A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

No Longer Available
N/A
US, Canada, RoW
Trabectedin
Janssen Research & Development, LLC
Sarcoma
 
 
GEICO 105-O, NCT05868889: Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD

Completed
N/A
43
Europe
Trabectedin and PLD
Grupo Español de Investigación en Cáncer de Ovario
Ovarian Cancer
06/22
06/22
PIPER, NCT04008238: Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients

Recruiting
N/A
200
Europe
Trabectedin
Institut Bergonié
Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Solitary Fibrous Tumors, Hemangioendothelioma, Desmoplastic Round Cell Tumor, Synovial Sarcoma
01/24
01/25
PROTraSarc, NCT06050434: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients

Completed
N/A
7
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar
Soft Tissue Sarcoma
07/24
07/24
Xadago (safinamide) / Meiji Seika, Zambon, Supernus Pharma
2016-000973-19: Study to verify safety and tolerability of the immediate switch from rasagiline (irreversible MAO-B inhibitor) and safinamide (reversible inhibitor of MAO-B) Studio per verificare la sicurezza e la tollerabilità nel passaggio immediato dal farmaco rasagilina (inibitore MAO-B irreversibile) al farmaco safinamide (inibitore MAO-B reversibile)

Not yet recruiting
4
20
Europe
Xadago, N04BD03, Tablet, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL, IRCCS San Raffaele Pisana
Parkinson's Disease Malattia di Parkinson, Parkinson's Disease Malattia di Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-003254-17: Safety and efficacy of Safinamide (Xadago®) in apathy associated with Parkinson's disease Seguridad y eficacia de la Safinamida (Xadago®) en la apatía asociada a la enfermedad de Parkinson

Ongoing
4
36
Europe
Film-coated tablet, Xadago
Institut de Recerca Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital de la Santa Creu i Sant Pau
Parkinson's disease Enfermedad de Parkinson, Parkinson's disease Enfermedad de Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002239-41: Effects of Safinamide therapy on reuroplasticity in patients with Parkinson's disease Effetti della safinamide in pazienti con malattia di Parkinson

Not yet recruiting
4
40
Europe
Xadago 50mg, NO4BD03, Film-coated tablet, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
I.R.C.C.S. FONDAZIONE S.LUCIA, Fondazione Santa Lucia
Parkinson's disease Malattia di Parkinson, Parkinson's disease Malattia di Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05312632: A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Completed
4
201
RoW
Safinamide Mesilate, Equfina, ME2125
Eisai Korea Inc.
Parkinson Disease
05/23
05/23
NCT03968744: Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Recruiting
4
23
Europe
Safinamide, Xadago
Alain Kaelin, Clinical Trial Unit Ente Ospedaliero Cantonale
Idiopathic Parkinson's Disease (at Later Stage)
04/25
04/25
2018-004892-11: A randomized, double-blind, placebo controlled, multicentre study to evaluate the effect of safinamide on freezing of gait (FOG) in mid- to late-stage fluctuating PD patients Studio multicentrico randomizzato, in doppio cieco, controllato con placebo di valutazione dell’effetto della safinamide sul freezing della marcia nei pazienti con malattia di parkinson in fase medio-avanzata

Not yet recruiting
3
128
Europe
Xadago, [043906039], Tablet, XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
OSPEDALE SANTA MARIA DELLA MISERICORDIA, Zambon s.p.a.
• Subjects of both genders over 18 years of age, with a clinical diagnosis of idiopathic PD• A Modified Hoehn and Yahr stage of = 4 in the “off” state;• A stable (4 weeks since last modification) anti-parkinsonian therapy; • The presence of FOG (defined as the persistence of gait hesitation and failure in starting the gait or the reported sensation of having the legs “frozen” or “glued to the ground”) even on an optimized dopaminergic treatment (patients with FOG item 3 score >0) • Soggetti maggiorenni con Malattia di Parkinson idiopatica;• Stadio Hoehn e Yahr di = 4 nello stato "off";• Una terapia antiparkinsoniana stabile (4 settimane dopo l'ultima modifica)• La presenza di FOG (definita come la persistenza di esitazione dell'andatura e fallimento nell'avvio dell'andatura o la sensazione riportata di avere le gambe "congelate" o "incollate a terra") anche su un trattamento dopaminergico ottimizzato (pazienti con punteggio all’item 3 del FOG-Q > 0), idiopathic Parkinson's disease (H & Y: = 4 in "off"); in stable therapy with hesitation of gait and failure to start gait or the feeling of having legs "glue to the ground" M. di Parkinson idiopatica (H&Y: = 4 in "off"); in terapia stabile con esitazione dell'andatura e fallimento nell'avvio dell'andatura o la sensazione riportata di avere le gambe "incollate a terra", Diseases [C] - Nervous System Diseases [C10]
 
 
SUCCESS, NCT03994328: An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD

Completed
N/A
1235
Europe
Zambon SpA, Iqvia Pty Ltd
Parkinson's Disease
12/23
12/23
NCT05225324: A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

Completed
N/A
702
RoW
Equfina 50 mg
Eisai Korea Inc.
Parkinson Disease
03/25
03/25
Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium

Not yet recruiting
3
28
Europe
QMF149, QVM149, Inhalation powder
University Medical Center Groningen, Novartis Pharma AG
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05562466: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Recruiting
3
200
Europe, RoW
QMF149, Budesonide
Novartis Pharmaceuticals
Asthma
02/28
05/28
NCT06077019: Role of Lung Function for Exercise Capacity in Well-trained Individuals

Recruiting
N/A
60
Europe
Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo
Morten Hostrup, PhD
Exercise Performance
07/26
12/26
NCT06067100: U-LABA/ICS Effects on Exercise Performance, Indacaterol

Recruiting
N/A
30
Europe
Indacaterol and Mometasonefluroate (low dose), Placebo, Indacaterol and Mometasonefluroate (high dose)
Morten Hostrup, PhD
Exercise Performance
07/26
12/26
NCT05217810: A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

Recruiting
N/A
600
RoW
Atectura inhalation capsule (150/80ug), Atectura inhalation capsule (150/160ug), Atectura inhalation capsule (150/320ug)
Novartis Pharmaceuticals
Asthma
12/26
12/26
Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
NCT05776927: A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Not yet recruiting
3
304
NA
QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149, Placebo to Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication, Rescue Medication, Concept 1 Device, Girohaler
Novartis Pharmaceuticals
Asthma
03/26
02/29
ADITION, NCT04656223: Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions

Completed
N/A
434
Europe
MF/IND/GLY plus sensor system, FDC therapy
Novartis Pharmaceuticals
Asthma
01/23
01/23
ChiCTR2300079273: Effect of Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose triple formulation on pulmonary function, symptoms and inflammation control in patients with asthma complicated with COPD

Not yet recruiting
N/A
96
 
Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose (160/150/50μg,qd); Budesonide formoterol inhalation powder aerosol (160/4.5 micrograms, 2 inhalations per bid) plus tiotropium bromide inhaler (2.5 micrograms, once a day, 2 inhalations per inhalation); Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol (160/4.8/7.2μg,bid,2 inhalations per inhalation)
Lishui People's Hospital; LiShui people's hospital, China Medical Foundation
asthma-COPD overlap
 
 
NCT05274425: A 24-week rPMS Study in Real-world Setting for Enerzair

Recruiting
N/A
600
RoW
Enerzair 150/50/80 μg, Enerzair 150/50/160 μg
Novartis Pharmaceuticals
Asthma
03/27
03/27
sabizabulin (VERU-111) / Veru Inc, Valeo Pharma
2021-001194-24: Clinical trial to Assess the Efficacy and Safety of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

Not yet recruiting
3
210
Europe
VERU-111, Capsule
Veru Inc., Veru Inc.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS), Coronavirus disease 2019 (COVID-19) in Patients at High Risk for Acute Respiratory Distress Syndrome, Diseases [C] - Virus Diseases [C02]
 
 
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
NCT03752099: To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Terminated
1b/2
80
US
VERU-111, Bisindole
Veru Inc.
Metastatic Castration Resistant Prostate Cancer
03/23
03/23
Redesca (low molecular weight heparin biosimilar) / Valeo Pharma
PRIORITY, NCT06153394: Prolonged Hypercoagulability Following Major Liver Resection for Malignancy

Not yet recruiting
3
50
Canada
Redesca (enoxaparin sodium for injection), Fragmin (dalteparin)
Western University, Canada, Valeo Pharma Inc
Hepatic Disease, Surgery-Complications, Hypercoagulability, Thrombosis
02/25
02/28
Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) / Novartis
2013-000581-10: Examining the effects of eye drops on changes in inflammation on the surface of the eye

Ongoing
4
100
Europe
latanoprost, travaprost, bimatoprost, tafluprost, Timolol maleate, Brimonidine tartrate, Brinzolamide, Dorzolamide hydrochloride, pilocarpine hydrochloride, Pilocarpine nitrate, N/A, Eye drops, solution, Eye drops, , Xalatan, Travatan, Lumigan, Saflutan, Timptol, Trusopt, Pilocarpine hydrochloride, N/A
Nottingham University NHS Trust
Glaucoma is the condition that is being treated by these eye drops - however the study is aimed at measuring the amount of inflammation that develops on the surface of the eye when these drops are used, Diseases [C] - Eye Diseases [C11]
 
 
NCT06883123: Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Recruiting
4
70
US
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Prairie Eye Center, Sengi
Open Angle Glaucoma
04/26
04/26
2020-000079-18: A phase III, multicentre, prospective, randomized, assessor-blinded, two-arm, parallel group, therapeutic non-inferiority 3-month clinical trial to compare the efficacy and safety of a generic fixed combination of brinzolamide 10 mg/mL + brimonidine tartrate 2 mg/mL eye drops suspension (Pharmathen) versus SIMBRINZA®/Alcon 10 mg/mL + 2 mg/mL eye drops suspension in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension

Ongoing
3
200
Europe
brinzolamide 10 mg/mL + brimonidine tartrate 2 mg/mL, SIMBRINZA, Eye drops, suspension, SIMBRINZA
Pharmathen S.A., Pharmathen S.A.
Open-angle glaucoma (OAG) or ocular hypertension (OHT) Γλαύκωμα ανοιχτής γωνίας ή ενδοφθάλμια υπερτονία, Glaucoma is a progressive multifactorial complex chronic optic neuropathy that constitutes a leading cause of irreversible blindness worldwide, with OAG being the most common form of the disease, Diseases [C] - Eye Diseases [C11]
 
 
ChiCTR1800015147: Measurement of the Rates of Retinal Nerve Fiber Layer Thinning to Guide Management of Myopic Glaucoma Patients

Suspended
N/A
203
 
Phase I: latanoprost 0.005% vs brinzolamide1%/brimonidine 0.2%. Phase II: Additional IOP lowering by 20% vs. continued treatment.
The Chinese University of Hong Kong; Level of the institution：, General Research Fund
Myopic Glaucoma
 
 

Download Options